WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

The Tracker / September 2025 / K251789

510(k) cleared

EMBOTRAP III Revascularization Device

Neuravi Limited · Sep 25, 2025 · K251789

FDA cleared the EMBOTRAP III Revascularization Device from Neuravi Limited on Sep 25, 2025 under K251789, a special 510(k). The device falls under product code NRY, Catheter, Thrombus Retriever, regulated at 21 CFR 870.1250 as a Class 2 device. The review panel was Cardiovascular.

FDA logged the submission as received on Jun 11, 2025. The decision came 106 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

This is the only decision on file for Neuravi Limited in the last 12 months of the tracker.

Questions & Answers

What did FDA clear under K251789?

K251789 is the FDA 510(k) for EMBOTRAP III Revascularization Device, submitted by Neuravi Limited. FDA's decision date was Sep 25, 2025, under product code NRY (Catheter, Thrombus Retriever).

Who makes the EMBOTRAP III Revascularization Device?

Neuravi Limited, based in Galway, is the applicant of record for K251789.

How long did the K251789 review take?

FDA received the submission on Jun 11, 2025 and issued its decision on Sep 25, 2025, 106 days later.

← All decisions in September 2025